Volinanserin

Drug Profile

Volinanserin

Alternative Names: 100,907; M 100907; MDL 100907

Latest Information Update: 13 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Insomnia; Schizophrenia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 May 2008 Efficacy data from the phase III NOCTURNE trial in insomnia released by sanofi-aventis
  • 13 Feb 2007 Volinanserin is still in phase II trials for Insomnia in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top